P503
Inter-subject variability explains juxtaposed effects in pharmacological treatments: an in-silico approach for the personalization of atrial fibrillation drug treatments

Cardiovascular Research

23 April 2018

Organised by:

Read full article

Contributors

A Liberos

A Liberos

Author

I Hernandez-Romero

I Hernandez-Romero

Author

A S De La Nava

A S De La Nava

Author

M Rodrigo

M Rodrigo

Author

A Bueno-Orovio

A Bueno-Orovio

Author

B Rodriguez

B Rodriguez

Author

M S Guillem

M S Guillem

Author

F Atienza

F Atienza

Author

A M Climent

A M Climent

Author

F Fernandez-Aviles

F Fernandez-Aviles

Author

You may be interested in

Congress Presentation

Combined SK and K2P channel block cardioverts atrial fibrillation in 82% of cases, doubling the efficacy of single channel block

1 September 2024

Congress Session

Update on antiarrhythmic therapy

31 March 2025

Congress Presentation

In-silico insights into the role of patient-specific fibrosis in personalised therapy selection for atrial fibrillation

1 September 2025

Congress Presentation

Drug-drug interactions of NOACs with comedication: prevalence and implications for adverse events in patients with atrial fibrillation

13 April 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources